Health Care [ 10/12 ] | Biotechnology [ 67/74 ]
NASDAQ | Common Stock
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment.
The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine.
In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab.
It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab).
The company was founded in 2008 and is based in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 10, 25 | 0.23 Increased by +2.20 K% | -0.11 Increased by +317.19% |
| Nov 7, 24 | 0.07 Increased by +75.00% | -0.17 Increased by +141.18% |
| Aug 8, 24 | -0.08 Decreased by -300.00% | -0.14 Increased by +42.86% |
| May 8, 24 | 0.17 Increased by +440.00% | -0.08 Increased by +312.50% |
| Mar 11, 24 | 0.01 Increased by +102.33% | -0.03 Increased by +133.33% |
| Nov 7, 23 | 0.04 Increased by +111.43% | -0.19 Increased by +121.05% |
| Aug 8, 23 | -0.02 Increased by +94.59% | -0.20 Increased by +90.00% |
| May 9, 23 | -0.05 Increased by +86.49% | -0.11 Increased by +54.55% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 38.09 M Increased by +43.17% | 18.88 M Increased by +2.16 K% | Increased by +49.55% Increased by +1.48 K% |
| Sep 30, 24 | 33.43 M Increased by +26.71% | 5.74 M Increased by +91.71% | Increased by +17.16% Increased by +51.30% |
| Jun 30, 24 | 25.11 M Increased by +1.58% | -6.53 M Decreased by -501.10% | Decreased by -26.02% Decreased by -491.75% |
| Mar 31, 24 | 41.46 M Increased by +76.45% | 13.79 M Increased by +1.52 K% | Increased by +33.26% Increased by +906.60% |
| Dec 31, 23 | 26.61 M Increased by +2.71 K% | 837.00 K Increased by +103.15% | Increased by +3.15% Increased by +100.11% |
| Sep 30, 23 | 26.38 M Increased by +55.98% | 2.99 M Increased by +113.21% | Increased by +11.34% Increased by +108.47% |
| Jun 30, 23 | 24.72 M Increased by +36.11% | -1.09 M Increased by +95.40% | Decreased by -4.40% Increased by +96.62% |
| Mar 31, 23 | 23.50 M Increased by +37.13% | -969.00 K Increased by +95.93% | Decreased by -4.12% Increased by +97.03% |